This is particularly marked in breast carcinoma cancer cell lines, with MCL1‐ and MARCH5‐dependent cells having similar sensitivity to haematologic cancer cell lines (acute myeloid leukaemia), where MCL1 inhibitors are in clinical development (Fig 4C). This evidence concerns the gene MARCHF5 and acute myeloid leukemia.